Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants

Citation
Lv. Gubareva et al., Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants, ANTIM AG CH, 45(12), 2001, pp. 3403-3408
Citations number
30
Categorie Soggetti
Microbiology
Journal title
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
ISSN journal
00664804 → ACNP
Volume
45
Issue
12
Year of publication
2001
Pages
3403 - 3408
Database
ISI
SICI code
0066-4804(200112)45:12<3403:COTAOZ>2.0.ZU;2-O
Abstract
RWJ-270201 is a novel cyclopentane inhibitor of influenza A and B virus neu raminidases (NAs). We compared the ability of RWJ-270201 to inhibit NA acti vity of clinical influenza isolates and viruses with defined resistance mut ations with that of zanamivir and oseltamivir carboxylate. In NA inhibition assays with influenza A viruses, the median 50% inhibitory concentration ( IC50) of RWJ-270201 (approximately 0.34 nM) was comparable to that of oselt amivir carboxylate (0.45 nM) but lower than that of zanamivir (0.95 nM). Fo r influenza B virus isolates, the IC50 of RWJ-270201 (1.36 nM) was comparab le to that of zanamivir (2.7 nM) and less than that of oseltamivir carboxyl ate (8.5 nM). A zanamivir-resistant variant bearing a Glu119-to-Gly (Glu119 --> Gly) or Glu119 --> Ala substitution in an NA (N2) remained susceptible to RWJ-270201 and oseltamivir carboxylate. However, a zanamivir-selected v ariant with an Arg292 --> Lys substitution in an NA (N2) showed a moderate level of resistance to RWJ-270201 (IC50 = 30 nM) and zanamivir (IC50 = 20 n M) and a high level of resistance to oseltamivir carboxylate (IC50 > 3,000 nM). The zanamivir-resistant influenza B virus variant bearing an Arg152 -- > Lys substitution was resistant to each NA inhibitor (IC50 = 100 to 750 nM ). The oseltamivir-selected variant (N1) with the His274 --> Tyr substituti on exhibited resistance to oseltamivir carboxylate (IC50 = 400 nM) and to R WJ-270201 (IC50 = 40 nM) but retained full susceptibility to zanamivir (IC5 0 = 1.5 nM). Thus, drug-resistant variants with substitutions in framework residues 119 or 274 can retain susceptibility to other NA inhibitors, where as replacement of functional residue 152 or 292 leads to variable levels of cross-resistance. We conclude that RWJ-270201 is a potent inhibitor of NAs of wild-type and some zanamivir-resistant or oseltamivir-resistant influen za A and B virus variants.